STAT3 may be activated by cytokines such as IL-6 and IL-10 that, released by tumor cells, besides acting in an autocrine fashion to sustain cancer cell survival, may activate this pathway in myeloid immune cells in the tumor environment, resulting in an impairment of their function (5). This evidence concerns the gene IL10 and neoplasm.